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ABSTRACT: Treatment of electron deficient pyridine N-oxides with 4-nitrobenzoyl chloride and a cyclic 
thioether in the presence of triethylamine leads to the corresponding 2-functionalized product in up to 
74% isolated yield. The transformation can also be accomplished with alternative nitrogen containing 
heterocycles including quinolines, pyrimidines, and pyrazines. To expand the scope of the transformation 
diisopropyl ether can be used as the reaction medium to allow for the use of solid thioether substrates. 
Nitrogen containing heterocycles including pyridines, quinolines, pyrazines, and pyrimidines are em-
bedded in many molecules of agrochemical and pharmaceutical significance.1 Methods for either the gen-
eration or selective functionalization of these heterocycles are therefore of great interest.2-4 2-Substituted 
derivatives represent an important subset of this family which show a broad spectrum of biological activ-
ities as exemplified by nexium, pirfenidone, boscalid, and lunesta (Figure 1) which contain carbon, oxy-
gen, chlorine, and nitrogen substitution at the 2-position respectively. 
  
 
Figure 1. Examples of 2-heteroatom substituted pyridine derivatives with biological activity. 
When compared to the introduction of nitrogen5 and oxygen6 heteroatoms at the 2-position of nitrogen 
containing heterocycles, the addition of a sulfur atom is a substantially less developed area. Two principal 
approaches have been developed for the introduction of a sulfur heteroatom: First, a SNAr reaction on a 
2-halo derivative, which is an effective strategy for electron deficient substrates.7 Second, the activation 
of heterocyclic N-oxides in the presence of a nucleophile. For example, PyBroP has been shown to be an 
excellent reagent to facilitate the addition of a thiol to the 2-position of a pyridine N-oxide.8 More recent 
methods for the sulfonylation of quinoline and pyridine N-oxides through reaction with sodium sul-
fonates,9 sulfonyl hydrazides,10 or sulfonyl chlorides11 have further expanded this toolbox. 
We recently described a simple and effective regioselective three-component coupling reaction of a pyr-
idine N-oxide 1, an acyl chloride and THF which led to the corresponding 2-functionalized pyridine 2 
(Scheme 1).12 We were interested to discover if a similar transformation could be performed using tetra-
hydrothiophene as a method to prepare 2-thio substituted pyridine derivatives. Reaction of 3-cyano-
pyridine N-oxide 1a (R1 = 3-CN) with 4-nitrobenzoyl chloride (R2 = 4-NO2C6H4, 2.2 equiv) and triethyl-
amine (2.2 equiv) in tetrahydrothiophene (0.2 M) at 50 °C overnight did not give 3, the analogous product 
to that observed using THF. Instead, the 2-substituted pyridine 4a (R1 = 3-CN) was isolated in an excellent 
74% yield. Within this transformation, a chloride had been incorporated into the product rather than a 
 molecule of 4-nitrobenzoate. Introduction of the chloride group provided greater potential for further 
functionalization and we believed this represented a promising new transformation. Within this manu-
script we describe the scope and limitations of this process, expand the transformation to encompass al-
ternative nitrogen containing heterocycles and show the reaction can be performed effectively in ethereal 
solvents allowing a significant reduction in the amount of sulfide nucleophile used. 
Scheme 1. Different Reactivity of Ethers and Thioethers 
 
Having showed the reaction was effective using 3-cyano pyridine N-oxide 1a as the substrate under the 
same conditions developed for the reaction of THF,12 we went on to examine alternative pyridine N-oxide 
substrates (Table 1). Whilst 4-cyanopyridine N-oxide 1b was a less effective substrate, the product was 
easily purified by column chromatography (entry 2; 28%). 3-Chloro and 4-chloropyridine N-oxide 1c and 
1d also gave the expected products in 51% and 39% yield respectively (entries 3 and 4). In addition, the 
di-substituted substrate 1g gave 4g in an excellent 60% yield (entry 7) providing an improved entry to a 
scaffold known to be a potent TRPV1 antagonist.13 The transformation requires an electron withdrawing 
group on the pyridine to proceed (1h, entry 8), although in an extreme case (4f, entry 6), this prevents O-
benzoylation, presumably due to the reduced nucleophilicity of the N-oxide. Blocking the 2-position of 
the pyridine ring resulted in O-benzoylation but this product did not lead to the 4-substituted derivative 
(entry 9). 
Table 1. Reaction of Pyridine N-Oxide Substratesa 
  
 
 
Encouraged by the excellent reactivity shown by pyridine N-oxide substrates we went on to examine 
alternative nitrogen containing heterocycles within the transformation (Table 2). Electron deficient quin-
oline N-oxides smoothly delivered the 2-substituted products (entries 1 and 2). 1,4-Pyrazine N-oxides 
(entries 3 and 4) and a pyrimidine N-oxide (entry 5; 63%) were also effective substrates. The transfor-
mation therefore appears to be effective across a range of heterocyclic N-oxides leading to functionalized 
products with excellent opportunities for further elaboration. 
Table 2. Reaction of Alternative Heterocyclic N-Oxides 
 
  
Despite the success observed in the reaction of the N-oxide substrates shown in Tables 1 and 2, a draw-
back of the overall transformation was using the sulfide as the reaction medium. This presented two dis-
tinct disadvantages to the process. First, the sulfide was used in vast excess; for example, in the reaction 
of tetrahydrothiophene with 3-cyanopyridine N-oxide 1a the sulfide was present in a 57 equiv excess 
(Table 1, entry 1). Second, the transformation was limited to sulfides which were liquids at 50 °C. We 
therefore sought to discover if a suitable solvent could be found to overcome these challenges (Table 3). 
Toluene proved ineffective, returning only starting material after reaction at 50 °C overnight. Both ace-
tonitrile (entry 2) and THF (entry 3) showed the presence of the desired product 4a in the crude reaction 
mixture along with a number of unidentified co-products that incorporated the solvent.14 Given the prom-
ise of THF we postulated that a more hindered ether may prove effective as the solvent. We initially 
examined eucalyptol which gave the product in 26% isolated yield (entry 5). We also examined a series 
of acyclic ethers with different steric demands (entries 6–9). From this study, diisopropyl ether emerged 
as the most effective solvent which was easy to handle at the operating temperature of the reaction (entry 
 9; 53%). Whilst this gave the product in a lower yield than when using the sulfide as the reaction solvent 
(Table 1, entry 1; 74%) the reduction to 5 equiv of sulfide provided distinct benefits. 
Table 3. Optimization of the Reaction Solventa 
 
Having discovered a suitable solvent with which to undertake the reaction we were able to explore the 
effect of changing the thioether substrate (Table 4). Crucially, adoption of a solvent allowed the use of 
solid thioether substrates (e.g. entry 7). Two key findings came from this part of the investigation. We 
were able to isolate products from the reaction of 3- and 4-membered thioethers which provided 2-substi-
tuted pyridine products (entries 1–3). This was in stark contrast to previous investigations where we were 
unable to isolate a product from the reaction using either epoxides or oxiranes.12 In addition, the ring size 
of the nucleophilic sulfide dictated which product was obtained from the reaction. Using the strained 
cyclohexene sulfide (entry 1) and thiirane (entry 2), the product from the transformation was the 4-nitro-
benzoate 3. With less strained 5- and 6-membered ring sulfides as substrates the product was the corre-
sponding chloride 4 (entries 5–8). Using thietane as the substrate gave mixtures of both the 4-nitrobenzo-
ate 3 and the chloride product 4, the ratio of which could be altered by changing the reaction temperature 
(entries 3 and 4). 
Table 4. Alternative Thioether Substrates 
  
 
The unexpected change in reaction outcome based upon the structure of the sulfide is intriguing and 
provides insight into the reaction mechanism. A potential mechanistic course for the process is presented 
in Scheme 2. O-Benzoylation of 1a followed by deprotonation leads to the carbene intermediate 13 which 
can combine with the sulfide to generate the ylide 14. Sulfur ylides are more stable than their correspond-
ing oxygen variants,15 which could provide the reason for the product divergence when changing from 
cyclic ethers to cyclic thioethers and the effect of different thioether substrates. Ylides derived from more 
strained sulfur nucleophiles will be less stable. Therefore, the reaction follows Path A, eliminating 4-
nitrobenzoate followed by recombination through ring opening to give the product 3a. Increasing the 
stability of the ylide through use of a less strained sulfide (Table 4, entries 5–8) slows down the elimination 
 of 4-nitrobenzoate and allows selective ring opening with the more nucleophilic chloride ion leading to 
4a (Path B).16 Consistent with this proposal, in reactions where mixtures of 3a and 4a are observed re-
ducing the temperature provides increased amounts of 4a (Table 4, entries 3 and 4). 
Scheme 2. Potential Mechanism for the Pyridine N-Oxide Functionalization 
The introduction of a chloride instead of a 4-nitrobenzoate in the reaction products was unexpected at 
the start of this work, however, the chloride is an extremely versatile functional group (Table 5). We 
examined the addition of a series of nitrogen (entry 1; 97% and entry 2; 36%), oxygen (entry 3; 97%), 
sulfur (entry 4; 96% and entry 5; 34%), phosphorous (entry 6; 32%) and carbon nucleophiles (entry 7; 
88%) to 4a to explore the flexibility of the transformation in synthesis. Overall, the product from this 
novel coupling process provides an effective substrate for further transformations to introduce diversity. 
Table 5. Functionalization of Pyridine Products 
 
 
 In summary, we have developed a simple and effective method for the regioselective functionalization 
of heterocyclic N-oxides through reaction with 4-nitrobenzoyl chloride and a cyclic sulfide under basic 
conditions. The transformation proceeds in higher yields than the related process involving cyclic ethers 
and is tolerant of a greater range of substrates. Thioethers within a strained 3- or 4-membered ring provide 
access to an alternative ester product. It is believed the divergence in the reaction pathways is due to the 
formation of a less-stable ylide intermediate when using thiirane and thietane derivatives as the reactive 
sulfide. Thioethers are significantly more reactive than ethers within this transformation such that ethers 
are effective solvents for the reaction allowing the use of solid sulfides within the process. The products 
can be used in a variety of substitution reactions suggesting they could be useful in the formation of 
nitrogen containing heterocycles of pharmaceutical and agrochemical interest. For example, 2-thio sub-
stituted pyridine N-oxides have been shown to have antibiotic activity.17 We are currently engaged in 
exploiting this transformation in discovery research and will report on our findings in due course. 
EXPERIMENTAL SECTION 
General Procedure A. The appropriate pyridine N-oxide (1.0 equiv) and 4-nitrobenzoyl chloride 
(2.2 equiv) were added to a 20 mL flame-dried microwave vial. The pressure was carefully restored using 
a nitrogen/argon balloon. The appropriate cyclic thioether (0.2 M) was introduced, and the mixture cooled 
to 0 °C. Triethylamine (2.2 equiv) was added, with rapid stirring of the reaction mixture. Following com-
pletion of addition, the cooling bath was removed and the mixture stirred for 5 minutes at room tempera-
ture before heating to 50 °C overnight. Ethyl acetate (EtOAc) (5 mL) was added, the mixture transferred 
to a round-bottomed flask and the volatiles were removed under reduced pressure. Compounds were pu-
rified by flash column chromatography, eluting with the stated solvent systems. 
General Procedure B. The appropriate pyridine N-oxide (1.0 equiv) and 4-nitrobenzoyl chloride 
(2.2 equiv) were added to a 20 mL flame-dried microwave vial. The pressure was carefully restored using 
a nitrogen/argon balloon. Diisopropyl ether (0.4 M) and the appropriate cyclic thioether (5.0 equiv) were 
introduced, and the mixture cooled to 0 °C. Triethylamine (2.2 equiv) was added, with rapid stirring of 
 the reaction mixture. Following completion of addition, the cooling bath was removed and the mixture 
stirred for 5 minutes at room temperature before heating to 50 °C overnight. EtOAc (5 mL) was added, 
the mixture transferred to a round-bottomed flask and the volatiles were removed under reduced pressure. 
Compounds were purified by flash column chromatography, eluting with the stated solvent systems. 
2-((4-Chlorobutyl)thio)nicotinonitrile (4a). Following General Procedure A, 3-cyanopyridine N-oxide 
(100 mg, 0.83 mmol) and 4-nitrobenzoyl chloride (339 mg, 1.83 mmol) in tetrahydrothiophene (THT) 
(0.2 M), after purification via flash column chromatography (dry loading, petroleum ether/EtOAc 10:1 
isocratic), afforded the title compound 4a (138 mg, 0.61 mmol, 74%) as a yellow oil. IR (ATR)/cm-1 3061, 
2936, 2864, 2222, 1571, 1549, 1443, 1391; 1H NMR (400 MHz, CDCl3) δ 8.57 (dd, J = 4.9 Hz, J = 1.8 
Hz, 1H), 7.79 (dd, J = 7.7 Hz, J = 1.8 Hz, 1H), 7.07 (dd, J = 7.7 Hz, J = 4.9 Hz, 1H), 3.58 (t, J = 6.3 Hz, 
2H), 3.31 (t, J = 6.9 Hz, 2H), 1.99–1.86 (m, 4H); 13C NMR (101 MHz, CDCl3) δ 163.0, 152.2, 140.7, 
118.6, 115.6, 107.7, 44.5, 31.6, 29.4, 26.6; LRMS (ES + APCI) m/z: calcd. for C10H1135ClN2S 226.0; 
found 227.0 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C10H1235ClN2S 227.0410; found 
227.0408. 
2-((4-Chlorobutyl)thio)isonicotinonitrile (4b). Following General Procedure A, 4-cyanopyridine N-oxide 
(100 mg, 0.83 mmol) and 4-nitrobenzoyl chloride (339 mg, 1.83 mmol) in THT (0.2 M), after purification 
via flash column chromatography (dry loading, petroleum ether/EtOAc 10:1 isocratic), afforded the ti-
tle compound 4b (52 mg, 0.23 mmol, 28%) as a yellow oil. IR (ATR)/cm-1 3050, 2925, 2853, 2237, 1584, 
1530, 1458, 1365; 1H NMR (400 MHz, CDCl3) δ 8.55 (d, J = 5.1 Hz, 1H), 7.38–7.36 (m, 1H), 7.15 (dd, 
J = 5.1 Hz, J = 1.4 Hz, 1H), 3.57 (t, J = 6.3 Hz, 2H), 3.22 (t, J = 7.0 Hz, 2H), 1.97–1.83 (m, 4H); 13C 
NMR (101 MHz, CDCl3) δ 161.5, 150.3, 124.0, 120.4, 120.0, 116.4, 44.5, 31.6, 29.3, 26.7; LRMS (ES + 
APCI) m/z: calcd. for C10H1135ClN2S 226.0; found 226.9 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. 
for C10H1235ClN2S 227.0410; found 227.0406. 
3-Chloro-2-((4-chlorobutyl)thio)pyridine (4c). Following General Procedure A, 3-chloropyridine N-oxide 
(108 mg, 0.83 mmol) and 4-nitrobenzoyl chloride (339 mg, 1.83 mmol) in THT (0.2 M), after purification 
 via flash column chromatography (dry loading, petroleum ether/EtOAc 10:1 isocratic), afforded the ti-
tle compound 4c (100 mg, 0.42 mmol, 51%) as a yellow oil. IR (ATR)/cm-1 3044, 2929, 2864, 1566, 1434, 
1387; 1H NMR (400 MHz, CDCl3) δ 8.33 (dd, J = 4.7 Hz, J = 1.5 Hz, 1H), 7.53 (dd, J = 7.8 Hz, J = 1.5 
Hz, 1H), 6.95 (dd, J = 7.8 Hz, J = 4.7 Hz, 1H), 3.58 (t, J = 7.0 Hz, 2H), 3.23 (t, J = 7.0 Hz, 2H), 1.99–
1.84 (m, 4H); 13C NMR (101 MHz, CDCl3) δ 157.4, 147.1, 135.9, 129.3, 119.7, 44.6, 31.8, 29.3, 26.7; 
LRMS (ES + APCI) m/z: calcd. for C9H1135Cl2NS 235.0; found 235.9 [M+H]+; HRMS (ESI, +ve) m/z: 
[M+H]+ calcd. for C9H1235Cl2NS 236.0067; found 236.0063. 
4-Chloro-2-((4-chlorobutyl)thio)pyridine (4d). Following General Procedure A, 4-chloropyridine N-ox-
ide (107.5 mg, 0.83 mmol) and 4-nitrobenzoyl chloride (339 mg, 1.83 mmol) in THT (0.2 M), after puri-
fication via flash column chromatography (dry loading, petroleum ether/EtOAc 10:1 isocratic), afforded 
the title compound 4d (77 mg, 0.33 mmol, 39%) as a yellow oil. IR (ATR)/cm-1 3042, 2933, 2864, 1562, 
1540, 1452, 1355; 1H NMR (400 MHz, CDCl3) δ 8.29 (d, J = 5.4 Hz, 1H), 7.18–7.16 (m, 1H), 6.97 (dd, 
J = 5.4 Hz, J = 1.9 Hz, 1H), 3.57 (t, J = 7.0 Hz, 2H), 3.20 (t, J = 7.0 Hz, 2H), 1.97–1.82 (m, 4H); 13C 
NMR (101 MHz, CDCl3) δ 161.0, 150.1, 143.9, 122.0, 120.0, 44.6, 31.7, 29.4, 26.8; LRMS (ES + APCI) 
m/z: calcd. for C9H1135Cl2NS 235.0; found 235.9 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C9H1235Cl2NS 236.0067; found 236.0063. 
2-((4-Chlorobutyl)thio)-3-nitropyridine (4e). Following General Procedure A, 3-nitropyridine N-oxide 
(116 mg, 0.83 mmol) and 4-nitrobenzoyl chloride (339 mg, 1.83 mmol) in THT (0.2 M), after purification 
via flash column chromatography (dry loading, petroleum ether/EtOAc 8:1 isocratic), afforded the ti-
tle compound 4e (75 mg, 0.30 mmol, 37%) as a yellow oil. IR (ATR)/cm-1 3076, 2931, 2860, 1584, 1554, 
1510, 1396, 1329; 1H NMR (400 MHz, CDCl3) δ 8.68 (dd, J = 4.6 Hz, J = 1.7 Hz, 1H), 8.48 (dd, J = 8.2 
Hz, J = 1.7 Hz, 1H), 7.19 (dd, J = 8.2 Hz, J = 4.6 Hz, 1H), 3.59 (t, J = 7.0 Hz, 2H), 3.26 (t, J = 7.0 Hz, 
2H), 2.01–1.85 (m, 4H); 13C NMR (101 MHz, CDCl3)  158.1, 153.2, 142.3, 133.9, 118.7, 44.6, 31.9, 29.8, 
26.2; LRMS (ES + APCI) m/z: calcd. for C9H1135ClN2O2S 246.0; found 246.9 [M+H]+; HRMS (ESI-TOF) 
m/z: [M+H]+ calcd. for C9H1235ClN2O2S 247.0308; found 247.0310. 
 5-Cyano-2-(trifluoromethyl)pyridine 1-oxide (1g).19 To a stirred mixture of 6-(trifluoromethyl)nicotinoni-
trile (1.00 g, 5.81 mmol) and urea-hydrogen peroxide addition complex (UHP) (1.15 g, 12.21 mmol) in 
CH2Cl2 (15 mL) was added trifluoroacetic anhydride (TFAA) (1.7 mL, 12.21 mmol) at 0 °C under argon. 
The reaction was allowed to stir at room temperature for 0.5 h. Excess peroxide was destroyed by the 
addition of 10% aqueous potassium iodide solution (50 mL). The organic phase was washed with satu-
rated 10% aqueous Na2S2O3 solution (50 mL) and water (50 mL), then dried over MgSO4, and filtered. 
The filtrate was concentrated under reduced pressure before the residue was triturated by diethyl ether to 
afford the title compound 1g as an off-white solid (571 mg, 3.04 mmol, 52%). m.p. 94–96 °C; IR 
(ATR)/cm-1 3031, 2988, 2243, 1605, 1549, 1389, 1277, 1155; 1H NMR (500 MHz, CDCl3) δ 8.49 (br s, 
1H), 7.80 (d, J = 8.5 Hz, 1H), 7.53 (d, J = 8.5 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 143.8, 126.0, 
125.9–125.8 (m, 1C), 122.6, 119.2 (q, JFC = 271.6 Hz), 115.8, 113.1; 19F NMR (471 MHz, CDCl3) δ -
69.6 (s, 3F); LRMS (ES + APCI) m/z: calcd. for C7H3F3N2O 188.0; found 187.1 [M–H]+; HRMS (ESI-
TOF) m/z: [M+H]+ calcd. for C7H4F3N2O 189.0276; found 189.0274. 
2-((4-Chlorobutyl)thio)-6-(trifluoromethyl)nicotinonitrile (4g). Following General Procedure A, com-
pound 1g (100 mg, 0.53 mmol) and 4-nitrobenzoyl chloride (218 mg, 1.17 mmol) in THT (0.2 M), after 
purification via flash column chromatography (dry loading, petroleum ether/CH2Cl2 3:1 isocratic), af-
forded the title compound 4g (94 mg, 0.32 mmol, 60%) as a yellow oil. IR (ATR)/cm-1 3079, 2940, 2869, 
2230, 1579, 1361, 1333, 1143; 1H NMR (500 MHz, CDCl3) δ 7.96 (d, J = 7.5 Hz, 1H), 7.42 (d, J = 7.5 
Hz, 1H), 3.58 (t, J = 6.5 Hz, 2H), 3.33 (t, J = 6.5 Hz, 2H), 1.98–1.89 (m, 4H); 13C NMR (125 MHz, 
CDCl3) δ 164.6, 150.2 (q, JFC = 36.1 Hz, 1C), 142.3, 120.7 (q, JFC = 273.9 Hz, 1C), 115.1 (q, JFC = 2.8 
Hz, 1C), 114.5, 110.4, 44.3, 31.6, 29.9, 26.5; 19F NMR (471 MHz, CDCl3) δ -69.1 (s, 3F); LRMS 
(ES + APCI) m/z: calcd. for C11H1035ClF3N2S 294.0; found 295.0 [M+H]+; HRMS (ESI-TOF) m/z: 
[M+H]+ calcd. for C11H1135ClF3N2S 295.0284; found 295.0280. 
 2-((3-Cyanopyridin-2-yl)thio)cyclohexyl 4-nitrobenzoate (3j). Following General Procedure B, 3-cyano-
pyridine N-oxide (100 mg, 0.83 mmol), 4-nitrobenzoyl chloride (339 mg, 1.83 mmol) and 7-thiabicy-
clo[4.1.0]heptane (476 mg, 4.17 mmol) in diisopropyl ether (0.4 M), after purification via flash column 
chromatography (dry loading, petroleum ether/EtOAc 5:1 isocratic), afforded the title compound 3j (182 
mg, 0.48 mmol, 57%) as a yellow oil. IR (ATR)/cm-1 3050, 2933, 2856, 2224, 1720, 1571, 1525, 1391, 
1346, 1264; 1H NMR (500 MHz, CDCl3) δ 8.62 (dd, J = 5.0 Hz, J = 1.5 Hz, 1H), 8.18 (d, J = 9.0 Hz, 2H), 
8.03 (d, J = 9.0 Hz, 2H), 7.73 (dd, J = 8.0 Hz, J = 1.5 Hz, 1H), 7.08 (dd, J = 8.0 Hz, J = 5.0 Hz, 1H), 5.19 
(td, J = 9.0 Hz, J = 4.0 Hz, 1H), 4.43 (td, J = 9.0 Hz, J = 4.0 Hz, 1H), 2.37–2.23 (m, 2H), 1.90–1.66 (m, 
4H), 1.61–1.51 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 163.8, 162.4, 152.1, 150.6, 140.9, 135.8, 130.8, 
123.5, 119.0, 115.4, 108.1, 77.4, 75.9, 46.5, 31.3, 25.1, 23.4; LRMS (ES + APCI) m/z: calcd. for 
C19H17N3O4S 383.1; found 384.2 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C19H18N3O4S 
384.1018; found 384.1019. 
2-((3-Cyanopyridin-2-yl)thio)ethyl 4-nitrobenzoate (3k). Following General Procedure B, with stirring at 
25 °C overnight 3-cyanopyridine N-oxide (100 mg, 0.83 mmol), 4-nitrobenzoyl chloride (339 mg, 1.83 
mmol) and thiirane (250 mg, 4.15 mmol) in diisopropyl ether (0.4 M), after purification via flash column 
chromatography (dry loading, petroleum ether/EtOAc 5:1 isocratic), afforded the title compound 3k (112 
mg, 0.34 mmol, 41%) as off-white solid. m.p. 132–134 ℃; IR (ATR)/cm-1 3109, 3078, 2921, 2853, 2224, 
1714, 1608, 1569, 1525, 1391; 1H NMR (400 MHz, CDCl3) δ 8.56 (dd, J = 4.9 Hz, J = 1.8 Hz, 1H), 8.28 
(d, J = 9.0 Hz, 2H), 8.20 (d, J = 9.0 Hz, 2H), 7.83 (dd, J = 7.7 Hz, J = 1.8 Hz, 1H), 7.11 (dd, J = 7.7 Hz, 
J = 4.9 Hz, 1H), 4.65 (t, J = 6.4 Hz, 2H), 3.70 (t, J = 6.4 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 164.6, 
161.8, 152.3, 150.8, 141.0, 135.4, 130.9, 123.7, 119.2, 115.3, 107.9, 64.1, 28.7; LRMS (ES + APCI) m/z: 
calcd. for C15H11N3O4S 329.0; found 330.0 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C15H12N3O4S 330.0543; found 330.0545. 
3-((3-Cyanopyridin-2-yl)thio)propyl 4-nitrobenzoate (3l). Following General Procedure B, 3-cyano-
pyridine N-oxide (100 mg, 0.83 mmol), 4-nitrobenzoyl chloride (339 mg, 1.83 mmol) and thietane (308 
 mg, 4.15 mmol) in diisopropyl ether (0.4 M), after purification via flash column chromatography (dry 
loading, petroleum ether/EtOAc 5:1 isocratic), afforded the title compound 3l (48 mg, 0.14 mmol, 17%) 
as a yellow solid. m.p. 123–125 ℃; IR (ATR)/cm-1 3113, 3081, 2957, 2933, 2220, 1716, 1607, 1567, 
1519, 1385; 1H NMR (400 MHz, CDCl3) δ 8.52 (dd, J = 4.9 Hz, J = 1.8 Hz, 1H), 8.34–8.22 (m, 2H), 
8.27–8.22 (m, 2H) 7.80 (dd, J = 7.7 Hz, J = 1.8 Hz, 1H), 7.08 (dd, J = 7.7 Hz, 4.9 Hz, 1H), 4.52 (t, J = 
7.0 Hz, 2H), 3.45 (t, J = 7.0 Hz, 2H), 2.26 (app quint, J = 7.0 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 
164.7, 162.6, 152.2, 150.8, 140.8, 135.7, 130.9, 123.8, 118.8, 115.5, 107.8, 64.6, 28.6, 26.8; LRMS 
(ES + APCI) m/z: calcd. for C16H13N3O4S 343.1; found 344.0 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ 
calcd. for C16H14N3O4S 344.0705; found 344.0708. 
2-((3-Chloropropyl)thio)nicotinonitrile (4l). Following General Procedure B, with stirring at 25 °C over-
night 3-cyanopyridine N-oxide (100 mg, 0.83 mmol), 4-nitrobenzoyl chloride (339 mg, 1.83 mmol) and 
thietane (308 mg, 4.15 mmol) in diisopropyl ether (0.4 M), after purification via flash column chroma-
tography (dry loading, petroleum ether/EtOAc 5:1 isocratic), afforded the title compound 4l (100 mg, 
0.47 mmol, 57%) as a yellow oil. IR (ATR)/cm-1 3063, 2955, 2222, 1571, 1551, 1441, 1391; 1H NMR 
(400 MHz, CDCl3) δ 8.57 (dd, J = 4.9 Hz, J = 1.8 Hz, 1H), 7.79 (dd, J = 7.7 Hz, J = 1.8 Hz, 1H), 7.08 
(dd, J = 7.7 Hz, J = 4.9 Hz, 1H), 3.60 (t, J = 7.0 Hz, 2H), 3.42 (t, J = 7.0 Hz, 2H), 2.20 (app quint, J = 7.0 
Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 162.6, 152.3, 140.7, 118.7, 115.5, 107.7, 43.5, 32.0, 27.4; LRMS 
(ES + APCI) m/z: calcd. for C9H935ClN2S 212.0; found 212.9 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ 
calcd. for C9H1035ClN2S 213.0248; found 213.0248. 
2-((5-Chloropentyl)thio)nicotinonitrile (4m). Following General Procedure B, 3-cyanopyridine N-oxide 
(100 mg, 0.83 mmol), 4-nitrobenzoyl chloride (339 mg, 1.83 mmol) and thiane (424 mg, 4.15 mmol) in 
diisopropyl ether (0.4 M), after purification via flash column chromatography (dry loading, petroleum 
ether/EtOAc 8:1 isocratic), afforded the title compound 4m (66 mg, 0.28 mmol, 33%) as a yellow solid. 
m.p. 28–30 ℃; IR (ATR)/cm-1 3059, 2988, 2949, 2925, 2853, 2224, 1571, 1545, 1391; 1H NMR (400 
MHz, CDCl3) δ 8.57 (dd, J = 4.9 Hz, J = 1.8 Hz, 1H), 7.79 (dd, J = 7.7 Hz, J = 1.8 Hz, 1H), 7.07 (dd, J = 
 7.7 Hz, J = 4.9 Hz, 1H), 3.55 (t, J = 7.0 Hz, 2H), 3.28 (t, J = 7.0 Hz, 2H), 1.88–1.73 (m, 4H), 1.66–1.57 
(m, 2H); 13C NMR (101 MHz, CDCl3) δ 163.3, 152.2, 140.7, 118.5, 115.7, 107.7, 44.9, 32.2, 30.0, 28.6, 
26.2; LRMS (ES + APCI) m/z: calcd. for C11H1335ClN2S 240.0; found 241.1 [M+H]+; HRMS (ESI-TOF) 
m/z: [M+H]+ calcd. for C11H1435ClN2S 241.0566; found 241.0567. 
2-((2-((2-Chloroethyl)thio)ethyl)thio)nicotinonitrile (4n). Following General Procedure B, 3-cyano-
pyridine N-oxide (100 mg, 0.83 mmol), 4-nitrobenzoyl chloride (339 mg, 1.83 mmol) and 1,4-dithiane 
(500 mg, 4.15 mmol) in diisopropyl ether (0.4 M), after purification via flash column chromatography 
(dry loading, petroleum ether/EtOAc 7:1 isocratic), afforded the title compound 4n (78 mg, 0.30 mmol, 
36%) as an off-white solid. m.p. 58–60 ℃; IR (ATR)/cm-1 3057, 2964, 2946, 2929, 2222, 1571, 1553, 
1437, 1393; 1H NMR (400 MHz, CDCl3) δ 8.62 (dd, J = 4.9 Hz, J = 1.8 Hz, 1H), 7.82 (dd, J = 7.7 Hz, J 
= 1.8 Hz, 1H), 7.11 (dd, J = 7.7 Hz, J = 4.9 Hz, 1H), 3.75–3.69 (m, 2H), 3.48–3.42 (m, 2H), 3.04–2.98 
(m, 2H), 2.90–2.85 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 162.3, 152.4, 140.9, 119.0, 115.4, 107.8, 
43.1, 34.0, 31.6, 30.1; LRMS (ES + APCI) m/z: calcd. for C10H1135ClN2S2 258.0; found 259.0 [M+H]+; 
HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C10H1235ClN2S2 259.0130; found 259.0129. 
2-((5-Chloropentan-2-yl)thio)nicotinonitrile and 2-((4-chloropentyl)thio)nicotinonitrile (4o). Following 
General Procedure B, 3-cyanopyridine N-oxide (100 mg, 0.83 mmol), 4-nitrobenzoyl chloride (339 mg, 
1.83 mmol) and 2-methyltetrahydrothiophene (426 mg, 4.15 mmol) in diisopropyl ether (0.4 M), after 
purification via flash column chromatography (dry loading, petroleum ether/EtOAc 10:1 isocratic), af-
forded the title compound 4o (90 mg, 0.38 mmol, 45%) as a yellow oil in a 1:1 mixture of regioisomers. 
IR (ATR)/cm-1 3056, 2959, 2925, 2224, 1573, 1551, 1443, 1391; 1H NMR (400 MHz, CDCl3) δ 8.58–
8.54 (m, 2H), 7.80–7.76 (m, 2H), 7.09–7.03 (m, 2H), 4.18–4.01 (m, 2H), 3.57 (t, J = 6.4 Hz, 1H), 3.32–
3.26 (m, 3H), 2.04–1.80 (m, 8H), 1.52 (d, J = 6.4 Hz, 4H), 1.45 (d, J = 6.4 Hz, 2H); 13C NMR (101 MHz, 
CDCl3) δ 163.3, 163.1, 152.2, 140.8, 140.7, 118.6, 118.5, 115.7, 107.7, 107.6, 58.2, 44.8, 39.8, 39.2, 33.8, 
30.1, 29.7, 26.4, 25.5, 21.3 (2 C missing); LRMS (ES + APCI) m/z: calcd. for C11H1335ClN2S 240.0; found 
241.0 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C11H1435ClN2S 241.0561; found 241.0562. 
 3-Cyanoquinoline N-oxide.18 m-Chloroperoxybenzoic acid (<77%, 1.35 g, 7.79 mmol) was added portion-
wise to a solution of 3-cyanoquinoline (1.00 g, 6.49 mmol) in CH2Cl2 (17 mL) at 0 °C. Following com-
pletion of addition, the reaction mixture was stirred overnight at room temperature and subsequently 
quenched with a saturated aqueous solution of potassium carbonate (30 mL). The resulting layers were 
separated before the aqueous layer was extracted with chloroform (5 × 40 mL). The combined organic 
extracts were washed with NaHCO3 (50 mL) and brine (50 mL) before being dried, filtered and concen-
trated under reduced pressure. Further purification via flash column chromatography (dry loading, petro-
leum ether/EtOAc 3:1 isocratic), afforded the title compound as an off-white solid (473 mg, 2.78 mmol, 
43%). m.p. 156–158 °C; IR (ATR)/cm-1 3042, 2936, 2237, 1580, 1495, 1372, 1331, 1229; 1H NMR (500 
MHz, CDCl3) δ 8.74 (d, J = 8.5 Hz, 1H), 8.60 (s, 1H), 8.05 (s, 1H), 7.98–7.90 (m, 2H), 7.78 (app t, J = 
7.5 Hz, 1H); 13C NMR (101 MHz, DMSO-d6) δ 143.5, 134.9, 133.5, 130.6, 129.9, 129.2, 129.1, 120.2, 
115.1, 107.3; LRMS (ES + APCI) m/z: calcd. for C10H6N2O 170.1; found 171.0 [M+H]+; HRMS (ESI-
TOF) m/z: [M+H]+ calcd. for C10H7N2O 171.0558; found 171.0560. 
2-((4-Chlorobutyl)thio)quinoline-3-carbonitrile (6). Following General Procedure A, 3-Cyanoquinoline 
N-oxide (100 mg, 0.59 mmol) and 4-nitrobenzoyl chloride (241 mg, 1.29 mmol) in THT (0.2 M), after 
purification via flash column chromatography (dry loading, petroleum ether/EtOAc 10:1 isocratic), af-
forded the title compound 6 (102 mg, 0.37 mmol, 63%) as a yellow oil. IR (ATR)/cm-1 3050, 2933, 2860, 
2224, 1614, 1584, 1556, 1333; 1H NMR (500 MHz, CDCl3) δ 8.32 (s, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.82–
7.74 (m, 2H), 7.52 (ddd, J = 8.0 Hz, J = 7.0 Hz, 1.0 Hz, 1H), 3.63 (t, J = 6.5 Hz, 2H), 3.43 (t, J = 6.5 Hz, 
2H), 2.05–1.93 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 158.7, 148.7, 142.6, 133.0, 128.4, 128.3, 126.8, 
123.9, 115.9, 106.3, 44.5, 31.7, 29.5, 26.5; LRMS (ES + APCI) m/z: calcd. for C14H1335ClN2S 276.0; 
found 277.0 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C14H1435ClN2S 277.0566; found 
277.0570. 
3-Chloroquinoline N-oxide.18 m-Chloroperoxybenzoic acid (<77%, 1.27 g, 7.36 mmol) was added por-
tion-wise to a solution of 3-chloroquinoline (1.00 g, 6.13 mmol) in CH2Cl2 (16 mL) at 0 °C. Following 
 completion of addition, the reaction mixture was stirred overnight at room temperature and subsequently 
quenched with a saturated aqueous solution of potassium carbonate (30 mL). The resulting layers were 
separated before the aqueous layer was extracted with chloroform (5 × 40 mL). The combined organic 
extracts were washed with NaHCO3 (50 mL) and brine (50 mL) before being dried, filtered and concen-
trated under reduced pressure to afford the title compound as a pale yellow solid (1.04 g, 5.81 mmol, 
95%). m.p. 118–120 °C; IR (ATR)/cm-1 3066, 2921, 2851, 1580, 1556, 1361, 1216; 1H NMR (400 MHz, 
CDCl3) δ 8.66 (d, J = 8.4 Hz, 1H), 8.51 (d, J = 1.2 Hz, 1H), 7.78 (d, J = 8.4 Hz, 1H), 7.76–7.70 (m, 2H) 
7.69–7.63 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 140.6, 135.5, 130.5, 129.9, 129.8, 127.6, 127.5, 124.5, 
119.9; LRMS (ES + APCI) m/z: calcd. for C9H635ClNO 179.0; found 179.9 [M+H]+; HRMS (ESI-TOF) 
m/z: [M+H]+ calcd. for C9H735ClNO 179.0132; found 179.0133. 
3-Chloro-2-((4-chlorobutyl)thio)quinoline (7). Following General Procedure A, 3-Chloroquinoline N-ox-
ide (100 mg, 0.56 mmol) and 4-nitrobenzoyl chloride (229 mg, 1.23 mmol) in THT (0.2 M), after purifi-
cation via flash column chromatography (dry loading, petroleum ether/CH2Cl2 2:1 isocratic), afforded the 
title compound 7 (99 mg, 0.35 mmol, 62%) as a yellow oil. IR (ATR)/cm-1 3053, 2914, 2847, 1579, 1523, 
1469, 1383; 1H NMR (500 MHz, CDCl3) δ 7.97 (s, 1H), 7.93 (d, J = 8.5 Hz, 1H), 7.68–7.62 (m, 2H), 7.45 
(app t, J = 7.0 Hz, 1H), 3.63 (t, J = 6.5 Hz, 2H), 3.38 (t, J = 6.5 Hz, 2H), 2.05–1.94 (m, 4H); 13C NMR 
(125 MHz, CDCl3) δ 157.5, 146.4, 133.9, 129.8, 128.0, 127.2, 126.9, 126.4, 126.1, 44.7, 31.9, 29.6, 26.6; 
LRMS (ES + APCI) m/z: calcd. for C13H1335Cl2NS 285.0; found 285.9 [M+H]+; HRMS (ESI-TOF) m/z: 
[M+H]+ calcd. for C13H1435Cl2NS 286.0224; found 286.0227. 
3-Cyanopyrazine N-oxide.18 m-Chloroperoxybenzoic acid (<77%, 1.97 g, 11.42 mmol) was added por-
tion-wise to a solution of pyrazine-2-carbonitrile (1.00 g, 9.51 mmol) in CH2Cl2 (25 mL) at 0 °C. Follow-
ing completion of addition, the reaction mixture was stirred overnight at room temperature and subse-
quently quenched with a saturated aqueous solution of potassium carbonate (30 mL). The resulting layers 
were separated before the aqueous layer was extracted with chloroform (5 × 40 mL). The combined or-
ganic extracts were washed with NaHCO3 (50 mL) and brine (50 mL) before being dried, filtered and 
 concentrated under reduced pressure. Further purification via flash column chromatography (dry loading, 
petroleum ether/EtOAc 3:1 isocratic), afforded the title compound as an off-white solid (240 mg, 1.98 
mmol, 21%). m.p. 140–142 °C; IR (ATR)/cm-1 3059, 3013, 2903, 2200, 1579, 1456, 1415, 1279; 1H NMR 
(500 MHz, CDCl3) δ 8.53 (d, J = 4.0 Hz, 1H), 8.37 (d, J = 1.5 Hz, 1H), 8.22 (dd, J = 4.0 Hz, J = 1.5 Hz, 
1H); 13C NMR (125 MHz, CDCl3) δ 148.7, 138.3, 136.7, 134.2, 113.7; LRMS (ES + APCI) m/z: calcd. 
for C5H3N3O 121.0; found 122.1 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C5H4N3O 121.0271; 
found 121.0270. 
3-((4-Chlorobutyl)thio)pyrazine-2-carbonitrile (8). Following General Procedure A, 3-Cyanopyrazine N-
oxide (100 mg, 0.83 mmol) and 4-nitrobenzoyl chloride (338 mg, 1.82 mmol) in THT (0.2 M), after pu-
rification via flash column chromatography (dry loading, petroleum ether/EtOAc 6:1 isocratic), afforded 
the title compound 8 (105 mg, 0.46 mmol, 56%) as a yellow oil. IR (ATR)/cm-1 3070, 2927, 2864, 2230, 
1514, 1430, 1357, 1196; 1H NMR (500 MHz, CDCl3) δ 8.52 (d, J = 2.5 Hz, 1H), 8.32 (d, J = 2.5 Hz, 1H), 
3.58 (t, J = 6.5 Hz, 2H), 3.29 (t, J = 6.5 Hz, 2H), 1.98–1.88 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 
161.4, 146.0, 139.6, 128.4, 114.5, 44.3, 31.5, 29.4, 26.4; LRMS (ES + APCI) m/z: calcd. for C9H1035ClN3S 
227.0; found 228.0 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C9H1135ClN3S 228.0362; found 
228.0366. 
3-Chloropyrazine N-oxide.18 m-Chloroperoxybenzoic acid (<77%, 1.80 g, 10.50 mmol) was added por-
tion-wise to a solution of 2-chloropyrazine (1.00 g, 8.73 mmol) in CH2Cl2 (23 mL) at 0 °C. Following 
completion of addition, the reaction mixture was stirred overnight at room temperature and subsequently 
quenched with a saturated aqueous solution of potassium carbonate (30 mL). The resulting layers were 
separated before the aqueous layer was extracted with chloroform (5 × 40 mL). The combined organic 
extracts were washed with NaHCO3 (50 mL) and brine (50 mL) before being dried, filtered and concen-
trated under reduced pressure. Further purification via flash column chromatography (dry loading, petro-
leum ether/EtOAc 5:1 isocratic), afforded the title compound as an off-white solid (970 mg, 7.46 mmol, 
85%). m.p. 97–99 °C; IR (ATR)/cm-1 3053, 3005, 2979, 1582, 1445, 1409, 1272; 1H NMR (500 MHz, 
 CDCl3) δ 8.25 (d, J = 4.0 Hz, 1H), 8.15 (d, J = 1.5 Hz, 1H), 8.01 (dd, J = 4.0 Hz, J = 1.5 Hz, 1H); 13C NMR 
(125 MHz, CDCl3) δ 151.9, 146.1, 133.7, 133.3; LRMS (ES + APCI) m/z: calcd. for C4H335ClN2O 130.0; 
found 131.0 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C4H435ClN2O 130.9914; found 130.9915. 
2-Chloro-3-((4-chlorobutyl)thio)pyrazine (9). Following General Procedure A, 3-Chloropyrazine N-oxide 
(100 mg, 0.77 mmol) and 4-nitrobenzoyl chloride (315 mg, 1.69 mmol) in THT (0.2 M), after purification 
via flash column chromatography (dry loading, petroleum ether/CH2Cl2 3:1 isocratic), afforded the ti-
tle compound 9 (98 mg, 0.42 mmol, 54%) as a yellow oil. IR (ATR)/cm-1 3046, 2927, 2866, 1528, 1497, 
1432, 1337, 1143; 1H NMR (500 MHz, CDCl3) δ 8.29 (d, J = 2.5 Hz, 1H), 8.01 (d, J = 2.5 Hz, 1H), 3.58 
(t, J = 6.5 Hz, 2H), 3.20 (t, J = 6.5 Hz, 2H), 1.99–1.85 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 156.6, 
146.5, 141.8, 137.9, 44.5, 31.7, 29.6, 26.3 LRMS (ES + APCI) m/z: calcd. for C8H1035Cl2N2S 236.0; found 
236.4 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C8H1135Cl2N2S 237.0020; found 237.0024. 
5-Chloropyrimidine N-oxide.18 m-Chloroperoxybenzoic acid (<77%, 1.81 g, 10.50 mmol) was added por-
tion-wise to a solution of 5-chloropyrimidine (1.00 g, 8.73 mmol) in CH2Cl2 (23 mL) at 0 °C. Following 
completion of addition, the reaction mixture was stirred overnight at room temperature and subsequently 
quenched with a saturated aqueous solution of potassium carbonate (30 mL). The resulting layers were 
separated before the aqueous layer was extracted with chloroform (5 × 40 mL). The combined organic 
extracts were washed with NaHCO3 (50 mL) and brine (50 mL) before being dried, filtered and concen-
trated under reduced pressure. Further purification via flash column chromatography (dry loading, petro-
leum ether/EtOAc 3:1 isocratic), afforded the title compound as an off-white solid (874 mg, 6.72 mmol, 
77%). m.p. 108–109 °C; IR (ATR)/cm-1 3026, 3003, 2879, 1569, 1519, 1406, 1249; 1H NMR (500 MHz, 
CDCl3) δ 8.85 (s, 1H), 8.39 (s, 1H), 8.19 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 148.1, 143.6, 142.2, 
130.8; LRMS (ES + APCI) m/z: calcd. for C4H335ClN2O 130.0; found 130.8 [M+H]+; HRMS (ESI-TOF) 
m/z: [M+H]+ calcd. for C4H435ClN2O 131.0007; found 130.9996. 
5-Chloro-4-((4-chlorobutyl)thio)pyrimidine (10). Following General Procedure A, 5-Chloropyrimidine 
N-oxide (100 mg, 0.77 mmol) and 4-nitrobenzoyl chloride (315 mg, 1.69 mmol) in THT (0.2 M), after 
 purification via flash column chromatography (dry loading, petroleum ether/CH2Cl2 1:1 isocratic), af-
forded the title compound 10 (114 mg, 0.48 mmol, 63%) as a yellow oil. IR (ATR)/cm-1 3040, 2936, 2866, 
1543, 1415, 1370, 1132; 1H NMR (500 MHz, CDCl3) δ 8.82 (s, 1H), 8.38 (s, 1H), 3.58 (t, J = 6.5 Hz, 
2H), 3.20 (t, J = 6.5 Hz, 2H), 1.99–1.86 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 167.9, 155.3, 152.8, 
128.9, 44.4, 31.7, 29.1, 26.5; LRMS (ES + APCI) m/z: calcd. for C8H1035Cl2N2S 236.0; found 237.0 
[M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C8H1135Cl2N2S 237.0020; found 237.0025. 
2,6-Dichloropyridine N-oxide.18 m-Chloroperoxybenzoic acid (<77%, 1.40 g, 8.10 mmol) was added por-
tion-wise to a solution of 2,6-dichloropyridine (1.00 g, 6.76 mmol) in CH2Cl2 (18 mL) at 0 °C. Following 
completion of addition, the reaction mixture was stirred overnight at room temperature and subsequently 
quenched with a saturated aqueous solution of potassium carbonate (30 mL). The resulting layers were 
separated before the aqueous layer was extracted with chloroform (5 × 40 mL). The combined organic 
extracts were washed with NaHCO3 (50 mL) and brine (50 mL) before being dried, filtered and concen-
trated under reduced pressure. Further purification via flash column chromatography (dry loading, petro-
leum ether/EtOAc 5:1 isocratic), afforded the title compound as an off-white solid (420 mg, 2.58 mmol, 
38%). m.p. 135–137 °C; IR (ATR)/cm-1 3081, 2960, 2866, 1532, 1447, 1365, 1264, 1143; 1H NMR 
(500 MHz, CDCl3) δ 7.45 (d, J = 8.0 Hz, 2H), 7.12 (t, J = 8.0 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 
143.9, 125.2, 124.6; LRMS (ES + APCI) m/z: calcd. for C5H335Cl2NO 163.0; found 164.1 [M+H]+; 
HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C5H435Cl2NO 163.9664; found 163.9662. 
2-((4-Azidobutyl)thio)nicotinonitrile (17). A microwave vial, placed under an inert atmosphere, was 
charged with a solution of 4a (50 mg, 0.22 mmol) in dimethylformamide (DMF) (0.9 mL). To this solu-
tion was added sodium azide (86 mg, 1.33 mmol). The reaction mixture was stirred at 80 °C for 48 hours 
before being cooled to room temperature. A 1:1 mixture of EtOAc/H2O (10 mL) was added, the layers 
separated and the aqueous phase extracted with EtOAc (3 × 10 mL). The combined organic extracts were 
washed with brine (10 mL), dried over MgSO4, filtered and concentrated under reduced pressure to afford 
the title compound 17 (50 mg, 0.21 mmol, 97%) as a yellow oil. IR (ATR)/cm-1 3057, 2931, 2862, 2224, 
 1573, 1551, 1391; 1H NMR (500 MHz, CDCl3) δ 8.57 (dd, J = 5.0 Hz, J = 2.0 Hz, 1H), 7.79 (dd, J = 8.0 
Hz, J = 2.0 Hz, 1H), 7.07 (dd, J = 8.0 Hz, J = 5.0 Hz, 1H), 3.33 (t, J = 7.0 Hz, 2H), 3.29 (t, J = 7.0 Hz, 
2H) 1.87–1.80 (m, 2H), 1.79–1.72 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 163.0, 152.2, 140.7, 118.6, 
115.6, 107.7, 51.1, 29.6, 28.1, 26.6; LRMS (ES + APCI) m/z: calcd. for C10H11N5S 233.1; found 234.0 
[M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C10H12N5S 234.0808; found 234.0809. 
2-((4-Morpholinobutyl)thio)nicotinonitrile (18). To a microwave vial, charged with compound 4a (95 mg, 
0.38 mmol), was added morpholine (60 μL, 0.66 mmol). The reaction mixture was stirred at room tem-
perature for 48 hours. The solvent was removed under reduced pressure. A 1:1 mixture of EtOAc/H2O 
(10 mL) was added, the layers separated and the aqueous phase extracted with EtOAc (3 × 10 mL). The 
combined organic extracts were washed with brine (10 mL), dried over MgSO4, filtered and concentrated 
under reduced pressure to afford the crude product. Further purification was performed via flash column 
chromatography (petroleum ether 1:1 EtOAc, isocratic) to afford the title compound 18 (38 mg, 0.14 
mmol, 36%) as a yellow oil. IR (ATR)/cm-1 3072, 2934, 2853, 2804, 2222, 1573, 1549, 1391, 1166; 1H 
NMR (500 MHz, CDCl3) δ 8.55 (dd, J = 5.0 Hz, J = 1.5 Hz, 1H), 7.77 (dd, J = 7.5 Hz, J = 1.5 Hz, 1H), 
7.05 (dd, J = 7.5 Hz, J = 5.0 Hz, 1H), 3.70 (t, J = 5.0 Hz, 4H), 3.29 (t, J = 7.5 Hz, 2H), 2.46–2.40 (m, 4H), 
2.37 (t, J = 7.5 Hz, 2H), 1.81–1.73 (m, 2H), 1.69–1.62 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 163.4, 
152.2, 140.7, 118.5, 115.7, 107.6, 67.1, 58.5, 53.8, 30.2, 27.2, 25.8; LRMS (ES + APCI) m/z: calcd. for 
C14H19N3OS 277.1; found 278.1 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C14H20N3OS 
278.1322; found 278.1323. 
4-((3-Cyanopyridin-2-yl)thio)butyl acetate (19). To a microwave vial, charged with compound 4a (100 
mg, 0.44 mmol) in a solution of DMF (1.8 mL), was added sodium acetate (218 mg, 2.65 mmol). The 
reaction mixture was heated to 80 °C for 48 hours before being allowed to cool to room temperature. A 
1:1 mixture of EtOAc/H2O (10 mL) was added, the layers separated and the aqueous phase extracted with 
EtOAc (3 × 10 mL). The combined organic extracts were washed with brine (10 mL), dried over MgSO4, 
filtered and concentrated under reduced pressure to afford the title compound 19 (107 mg, 0.43 mmol, 
 97%) as a yellow oil. IR (ATR)/cm-1 3065, 2946, 2864, 2224, 1731, 1573, 1549, 1391, 1233; 1H NMR 
(400 MHz, CDCl3) δ 8.56 (dd, J = 4.8 Hz, J = 1.6 Hz, 1H), 7.78 (dd, J = 8.0 Hz, J = 1.6 Hz, 1H), 7.06 
(dd, J = 8.0 Hz, J = 4.8 Hz, 1H), 4.13–4.08 (m, 2H), 3.32–3.28 (m, 2H), 2.05 (s, 3H), 1.84–1.77 (m, 4H); 
13C NMR (101 MHz, CDCl3) δ 171.3, 163.2, 152.2, 140.7, 118.6, 115.7, 107.7, 63.9, 29.8, 27.9, 25.9, 
21.1; LRMS (ES + APCI) m/z: calcd. for C12H14N2O2S 250.1; found 251.0 [M+H]+; HRMS (ESI-TOF) 
m/z: [M+H]+ calcd. for C12H15N2O2S 251.0849; found 251.0850. 
S-(4-((3-Cyanopyridin-2-yl)thio)butyl) ethanethioate (20). To a microwave vial, charged with compound 
4a (50 mg, 0.22 mmol) in a solution of DMF (1.1 mL), was added potassium thioacetate (152 mg, 1.32 
mmol) and potassium iodide (8.2 mg, 0.04 mmol). The reaction mixture was heated to 80 °C for 48 hours 
before being allowed to cool to room temperature. A 1:1 mixture of EtOAc/H2O (10 mL) was added, the 
layers separated and the aqueous phase extracted with EtOAc (3 × 10 mL). The combined organic extracts 
were washed with brine (10 mL), dried over MgSO4, filtered and concentrated under reduced pressure to 
afford the title compound 21 (56 mg, 0.21 mmol, 96%) as a yellow oil. IR (ATR)/cm-1 3063, 2923, 2851, 
2222, 1683, 1571, 1549, 1391, 1138; 1H NMR (400 MHz, CDCl3) δ 8.56 (dd, J = 4.8 Hz, J = 1.6 Hz, 1H), 
7.78 (dd, J = 7.6 Hz, J = 1.6 Hz, 1H), 7.06 (dd, J = 7.6 Hz, J = 4.8 Hz, 1H), 3.27 (t, J = 7.2 Hz, 2H), 2.91 
(t, J = 7.2 Hz, 2H), 2.32 (s, 3H), 1.85–1.69 (m, 4H); 13C NMR (101 MHz, CDCl3) δ 195.9, 163.1, 152.2, 
140.7, 118.6, 115.7, 107.6, 30.8, 29.6, 28.8, 28.6, 28.4; LRMS (ES + APCI) m/z: calcd. for C12H14N2OS2 
266.1; found 267.0 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C12H15N2OS2 267.0620; found 
267.0621. 
2-((4-((4-Methoxyphenyl)thio)butyl)thio)nicotinonitrile (21). To a microwave vial, charged with com-
pound 4a (50 mg, 0.22 mmol) in a solution of DMF (1.1 mL), was added 4-methoxybenzenethiol (63 mg, 
0.44 mmol) and caesium carbonate (216 mg, 0.66 mmol). The reaction mixture was heated to 80 °C for 
48 hours before being allowed to cool to room temperature. A 1:1 mixture of EtOAc/H2O (10 mL) was 
added, the layers separated and the aqueous phase extracted with EtOAc (3 × 10 mL). The combined 
organic extracts were washed with brine (10 mL), dried over MgSO4, filtered and concentrated under 
 reduced pressure to afford the title compound 23 (25 mg, 0.08 mmol, 34%) as an off-white solid. m.p. 
38–40 °C; IR (ATR)/cm-1 3066, 2949, 2830, 2220, 1571, 1553, 1493, 1395, 1235; 1H NMR (400 MHz, 
CDCl3) δ 8.55 (dd, J = 5.2 Hz, J = 1.6 Hz, 1H), 7.77 (dd, J = 7.6 Hz, J = 1.6 Hz, 1H), 7.34 (d, J = 8.8 Hz, 
2H), 7.05 (dd, J = 7.6 Hz, J = 5.2 Hz, 1H), 6.83, (d, J = 8.8 Hz, 2H), 3.80 (s, 3H), 3.25 (t, J = 7.2 Hz, 2H), 
2.85 (t, J = 7.2 Hz, 2H), 1.90–1.81 (m, 2H), 1.77–1.68 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 163.2, 
159.1, 152.2, 140.7, 133.5, 126.4, 118.5, 115.7, 114.7, 107.6, 55.5, 35.5, 29.8, 28.4, 28.1; LRMS (ES + 
APCI) m/z: calcd. for C17H18N2OS2 330.1; found 331.0 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. 
for C17H19N2OS2 331.0939; found 331.0936. 
Diethyl (4-((3-cyanopyridin-2-yl)thio)butyl)phosphonate (22). To a microwave vial, charged with com-
pound 4a (50 mg, 0.22 mmol), was added triethyl phosphite (484 mg, 2.92 mmol). The reaction mixture 
was heated to 160 °C for 48 hours before being allowed to cool to room temperature. A 1:1 mixture of 
EtOAc/H2O (10 mL) was added, the layers separated and the aqueous phase extracted with EtOAc (3 × 
10 mL). The combined organic extracts were washed with brine (10 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure. Further purification via flash column chromatography (dry loading, 
petroleum ether/EtOAc 3:1 isocratic), afforded the title compound 24 (23 mg, 0.07 mmol, 32%) as an 
orange oil. IR (ATR)/cm-1 3047, 2931, 2867, 2222, 1573, 1551, 1391, 1231, 1017, 956; 1H NMR 
(500 MHz, CDCl3) δ 8.56 (d, J = 4.0 Hz, 1H), 7.77 (d, J = 7.5 Hz, 1H), 7.05 (dd, J = 7.5 Hz, J = 4.0 Hz, 
1H), 4.18–4.02 (m, 4H), 3.27 (t, J = 6.0 Hz, 2H), 1.88–1.72 (m, 6H), 1.32 (t, J = 6.0 Hz, 6H); 13C NMR 
(101 MHz, CDCl3) δ  163.1, 152.2 (d, JPC = 18.5 Hz, 1C), 140.7 (d, JPC = 9.0 Hz, 1C), 118.6, 115.6, 107.6, 
62.0–60.4 (m, 2C), 31.2–28.3 (m, 3C), 22.3 (d, JPC = 107.5 Hz 1C), 16.6 (d, JPC = 66. 8 Hz, 2C); 31P NMR 
(202 MHz, CDCl3) δ 35.2–28.5 (m, 1P); LRMS (ES + APCI) m/z: calcd. for C14H21N2O3PS 328.1; found 
328.7 [M+H]+; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C14H22N2O3PS 329.1089; found 329.1087. 
2-((4-Cyanobutyl)thio)nicotinonitrile (23). A microwave vial, placed under an inert atmosphere, was 
charged with a solution of 4a (50 mg, 0.22 mmol) in DMF (0.8 mL). To this solution was added potassium 
cyanide (29 mg, 0.44 mmol) and potassium iodide (2.2 mg, 0.01 mmol). The reaction mixture was stirred 
 at room temperature for 18 hours. A 1:1 mixture of EtOAc/H2O (10 mL) was added, the layers separated 
and the aqueous phase extracted with EtOAc (3 × 10 mL). The combined organic extracts were washed 
with brine (10 mL), dried over MgSO4, filtered and concentrated under reduced pressure to afford the title 
compound 25 (42 mg, 0.19 mmol, 88%) as a yellow oil. IR (ATR)/cm-1 3055, 2936, 2856, 2243, 2222, 
1571, 1551, 1391; 1H NMR (400 MHz, CDCl3) δ 8.57 (dd, J = 4.8 Hz, J = 1.6 Hz, 1H), 7.79 (dd, J = 7.6 
Hz, J = 1.6 Hz, 1H), 7.08 (dd, J = 7.6 Hz, J = 4.8 Hz, 1H), 3.30 (t, J = 6.8 Hz, 2H), 2.42 (t, J = 6.8 Hz, 2H), 
1.95–1.78 (m, 4H); 13C NMR (101 MHz, CDCl3) δ 162.6, 152.3, 140.8, 119.4, 118.8, 115.5, 107.7, 29.0, 
28.4, 24.5, 16.9; LRMS (ES + APCI) m/z: calcd. for C11H11N3S 217.1; found 218.0 [M+H]+; HRMS (ESI-
TOF) m/z: [M+H]+ calcd. for C11H12N3S 218.0746; found 218.0744. 
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